The attached publication in the “Journal of Diabetic Complications & Medicine” by the authors Jonathan Rosenblum and Menachem Oberbaum describes the first ever experience with Curasite® in man. This pilot study led to the larger double-blind effort that resulted in FDA clearance of the product.
The pilot study showed strong evidence of a wound healing effect by Curasite to treat resistant diabetic foot ulcers (DFUs) with many patients achieving complete wound closure, results that were replicated in the larger blinded multi-center study.
The FDA has cleared Curasite for the following prescription uses:
- Diabetic foot ulcers
- Leg ulcers, including venous stasis ulcers, arterial ulcers, and ulcers of mixed etiology
- Full and partial thickness pressure ulcers
- 1st and 2nd-degree partial thickness burns.
Curasite is also approved for the following over the counter (OTC) uses:
- Minor abrasions
- Minor lacerations
- Minor cuts
- Minor scalds and burns.
The FDA claims are extensive and, importantly, position Curasite as first-line therapy for these patients. Due to the unprecedented efficacy of Curasite, Izun intends to pursue other indications for this remarkable wound healing product.